JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Predictive Value of IHC4 Score for Pathological Response to Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer
Elsamany, Shereef; Elmorsy, Soha; Alzahrani, Abdullah; Rasmy, Ayman; Abozeed, Waleed N; Mohammed, Amrallah A; Sherisher, Mohamed A; Abbas, Mohammed M; Mashhour, Miral;
  PDF(new window)
 Abstract
Purpose: This study aimed to explore the value of IHC4 in predicting pathological response after neoadjuvant chemotherapy in patients with hormonal receptor (HR)-positive breast cancer (BC). Materials and Methods: In this retrospective exploratory study, data for 68 HR-positive BC patients who received neoadjuvant chemotherapy were recorded. IHC4 scores were calculated based on estrogen receptors/progesterone receptors, Ki-67 and HER2 status. Logistic and ordinal regression analyses in addition to likelihood ratio test were used to explore associations of IHC4 scores and other clinico-pathological parameters with pathological complete response (pCR) and pathological stage. Results: Taking the 25th percentile as the cut-off, a lower IHC4 score was associated with an increased probability of pCR (low; 52.9% vs. High; 21.6%, OR
 Keywords
IHC4 score;neoadjuvant chemotherapy;pathological response;hormonal receptors;breast cancer;
 Language
English
 Cited by
1.
Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy, Biotechnic & Histochemistry, 2017, 92, 3, 175  crossref(new windwow)
 References
1.
Aapro M (2011). Neoadjuvant therapy in breast cancer: can we define its role? The Oncologist, 6, 36-39.

2.
Barrios CH, Sampaio C, Vinholes J, et al (2009). What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol, 20, 1157-62. crossref(new window)

3.
Bear HD, Anderson S, Brown A, et al (2003). The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21, 4165-74. crossref(new window)

4.
Chang JC, Makris A, Gutierrez MC, et al (2008). Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat, 108, 233-40. crossref(new window)

5.
Christiansen J, Bartlett J, Gustavson M, et al (2012). Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. J Clin Oncol, 30, 517.

6.
Colleoni M, Montagna E (2012). Neoadjuvant therapy for ERpositive breast cancers. Ann Oncol, 23, 243-48. crossref(new window)

7.
Colleoni M, Viale G, Zahrieh D, et al (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res, 10, 6622-8. crossref(new window)

8.
Cortazar P, Zhang L, Untch M, et al (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384, 164-72. crossref(new window)

9.
Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor-2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. crossref(new window)

10.
Dowsett M, Cuzick J, Wale C, et al (2010). Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol, 28, 1829-34. crossref(new window)

11.
Gianni L, Eiermann W, Semiglazov V, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84. crossref(new window)

12.
Gianni L, Zambetti M, Clark K, et al (2005). Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol, 23, 7265-77. crossref(new window)

13.
Kim MM, Allen P, Gonzalez-Angulo AM, et al (2013). Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol, 24, 1999-2004. crossref(new window)

14.
Kaufmann M, Von Minckwitz G, Mamounas EP, et al (2012). Recommendations from an International consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol, 19, 1508-16. crossref(new window)

15.
Lonning PE (2012). Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol, 4, 127-37. crossref(new window)

16.
Penault-Llorca F, Andre F, Sagan C, et al (2009). Ki67 Expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol, 27, 2809-15. crossref(new window)

17.
Peto R, Davies C, Godwin J, et al (2012). Comparisons between different polychemotherapy regimens for early breast cancer meta-analysis of long-term outcome among 100.000 women in 123 randomised trials. Lancet, 379, 432-44. crossref(new window)

18.
Telli ML (2013). Insight or confusion: survival after responseguided neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 31, 3613-5. crossref(new window)

19.
Untch M, Fasching PA, Konecny GE, et al (2011). Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favourable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO Trial of the AGO and GBG Study Groups. J Clin Oncol, 29, 3351-7. crossref(new window)

20.
Von Minckwitz G, Untch M, Nuesch E, et al (2011). Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast Cancer Res Treat, 125, 145-56. crossref(new window)